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Abstract
Lactate is increasingly recognised to be more than a simple end product of anaerobic glycolysis. Skeletal muscle and white adipose tissue
are considered to be the main sites of lactate production and release. Recent studies have demonstrated that there is a specific G-protein
coupled receptor for lactate, GPR81, which is expressed primarily in adipose tissue, and also in muscle. Lactate inhibits lipolysis in adipose
tissue by mediating, through GPR81, the anti-lipolytic action of insulin. A high proportion (50 % or more) of the glucose utilised by white
adipose tissue is converted to lactate and lactate production by the tissue increases markedly in obesity; this is likely to reflect a switch
towards anaerobic metabolism with the development of hypoxia in the tissue. During exercise, there is a shift in fuel utilisation by
muscle from lipid to carbohydrate, but this does not appear to be a result of the inhibition of lipolysis in the main adipose tissue
depots by muscle-derived lactate. It is suggested instead that a putative autocrine lactate loop in myocytes may regulate fuel utilisation
by muscle during exercise, operating via a muscle GPR81 receptor. In addition to being an important substrate, lactate is a key signal
in metabolic regulation.
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Lactate is a major end product of the metabolism of glucose
by cells through the glycolytic pathway. Skeletal muscle is
considered to be the main organ of lactate production, but
adipose tissue is also quantitatively important. Typically, the
production of lactate is increased as oxidative metabolism
falls when oxygen levels are low, being maximal under con-
ditions of anoxia. During exercise, however, the production
and release of lactate from skeletal muscle are greatly elevated
as a result of an increased glycolytic rate subsequent to the
stimulation of glycogenolysis and of glucose uptake as oxi-
dative phosphorylation approaches maximal rates. Although
lactate is utilised for the synthesis of glucose in the liver by
gluconeogenesis and as a fuel in oxidative tissues, until
recently it has been widely considered as a metabolic end pro-
duct and the cause of acidosis-induced peripheral fatigue.
However, perspectives on the physiological role of lactate
have changed radically and it is now evident that it functions
as a distinct metabolic signal, with its reported actions
including the induction of insulin resistance in skeletal
muscle(1) and the stimulation of inflammation in L6 cells and
macrophages(2).
Recent studies(3) have demonstrated that there is a specific
lactate receptor through which the metabolite has a marked
anti-lipolytic action. Importantly, lactate has now been
shown to mediate the well-recognised anti-lipolytic effect of
insulin(4). The new perspectives on lactate as a key metabolic
regulator are considered here, together with the potential
implications for both the sparing of fat oxidation in muscle
during high-intensity exercise and adipose tissue function
in obesity.
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GPR81 – the lactate receptor
Several G-protein coupled receptors are expressed in adipose
tissue, some of which are regarded as orphan receptors.
These include the G-protein coupled receptor subfamily of
hydroxy-carboxylic acid receptors, the ligands of which are
intermediates in energy metabolism. One particular member
of this subfamily, GPR81, has been found to be a selective
receptor for lactate(3,4). The related protein, GPR109A, is a
receptor for the ketone body 3-hydroxybutyrate, while
GPR109B is a receptor for 3-hydroxy-octanoate and other
3-hydroxylated b-oxidation products(5). Lactate is not,
however, an agonist for GPR109A or GPR109B.
GPR81 appears to be expressed principally in adipose
tissue(3), although limited expression is also evident for liver
and kidney as well as in skeletal muscle. Expression is high
in each of the major white adipose tissue depots and also
occurs in brown, as well as white, fat(3). Cell culture studies
with 3T3-L1 adipocytes indicate that GPR81 is expressed,
and receptor protein found, only in differentiated adipocytes;
minimal or no GPR81 gene expression or protein is evident
before the induction of differentiation in 3T3-L1 cells(3).
Although little is known on the regulation of GPR81
expression in adipocytes, in microarray studies we have
noted a strong down-regulation of GPR81 gene expression
in human adipocytes exposed to macrophage-conditioned
medium over 24 h(6). This suggests that macrophage-derived
inflammatory factors, such as TNF-a and IL-1b, may play an
important regulatory role in GPR81 expression.
Lactate and lipolysis
The binding of L-lactate to the GPR81 receptor leads to a
Gi-dependent inhibition of adenyl cyclase and thus of cyclic
AMP (cAMP) accumulation. It also inhibits the forskolin-induced
increase in cAMP level(3) and the increase stimulated by
isoprenaline(4). These observations are consistent with
the physiological evidence that lactate can have a direct anti-
lipolytic action, given that cAMP is a key mediator in the control
of lipolysis. Indeed, the increased circulating lactate levels
associated with severe exercise were proposed in the 1970s as
leading to the inhibition of lipolysis(7), and an anti-lipolytic
action of the metabolite was first indicated at that time(8). No
effect of lactate is evident, however, in humans infusedwith con-
centrations of lactate up to 2·4 mM(9), and lactate has been
reported to inhibit stimulated, though not basal, lipolysis(10).
Lactate, at concentrations of 5 mM and above, has now
been shown to inhibit both glycerol and NEFA release from
adipocytes in cell culture(3). This direct anti-lipolytic action
of lactate has been documented in white adipocytes from
rodents and from humans(3). Studies on transgenic GPR81-
deficient mice have demonstrated that the effect is mediated
through the GPR81 receptor since in these animals, in contrast
to the wild-type, the anti-lipolytic effect of lactate is essentially
abolished(4). Although the published data relate to white
adipocytes, presumably lactate has a similar anti-lipolytic
action in brown fat, given the presence of the GPR81 receptor
in brown adipocytes, in addition to white.
Lactate mediates the anti-lipolytic effect of insulin
The concept that lactate binds to the adipocyte GPR81 recep-
tor reducing cAMP levels and thereby suppressing lipolysis
has recently been subject to a further major development.
It has, of course, long been recognised that a number of
hormones and other factors have lipolytic or anti-lipolytic
actions, with noradrenaline released from sympathetic nerve
endings being considered as the main physiological stimulator
of lipolysis(11). Of the several known anti-lipolytic factors, insu-
lin plays a particularly prominent role; indeed, the inhibition of
lipolysis is an important action of insulin. In a key study pub-
lished recently, the anti-lipolytic action of insulin was reported
to be mediated by lactate through the GPR81 receptor(4).
Several strands of evidence point to lactate mediating the
insulin-dependent inhibition of lipolysis via GPR81. At the cel-
lular level, while isoprenaline stimulates lipolysis in both
wild-type and GPR81-deficient mice, the anti-lipolytic effect of
insulin in the presence of high levels of glucose is greatly
attenuated in white adipocytes from the deficient mice(4).
Lactate is, of course, released from adipocytes following
insulin-dependent glucose uptake. Similarly, administration of
glucose to wild-type mice resulted in a marked decrease in
cAMP levels in white adipose tissue, but in GPR81-deficient
mice the effect was reduced(4). Further, in in vivo studies with
mice, the intraperitoneal injection of glucose resulted in
increased release of lactate and a fall in NEFA release from
subcutaneous white adipose tissue in wild-type animals. In
GPR81-deficient mice, however, although lactate release was
unaltered relative to the wild-type, the release of NEFAs was
not inhibited despite similar plasma insulin levels in the two
groups(4). Parallel results were obtained in terms of plasma
levels; lactate, glucose and insulin were the same, but a rapid
and marked fall in NEFA concentration was only evident in the
wild-type animals.
From these results, it is proposed that within white adipose
tissue an autocrine/paracrine loop operates in which lactate
derived from glucose, especially postprandially following the
insulin-stimulated increase in glucose uptake, mediates the
anti-lipolytic effect of insulin(4). As a consequence, in the pre-
sence of carbohydrate, lipid is retained by adipocytes. In the
following sections, we consider the implications of this
perspective in relation to adipose tissue function in obesity
and to substrate utilisation by muscle during exercise.
Lactate production by adipose tissue
As emphasised earlier, white adipose tissue is an important
site of lactate production in whole-body terms. Lactate has
been described as a major metabolite of glucose in adipocytes,
particularly in large fat cells(12,13). Indeed, there is a strong
correlation between fat cell size and the relative conversion
of glucose to lactate, with between 50 and 70 % of glucose
being converted to lactate in adipocytes from the obese(13–15).
Thus lactate production in adipose tissue increases in obesity,
with raised concentrations of the metabolite in the
tissue(13,16,17). It is suggested that the enlarged white adipose
tissue mass in obese subjects may lead to a 5- to 8-fold
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increase in lactate release from the tissue relative to lean
subjects, and there is a correlation between plasma lactate
and BMI(13).
The increased lactate production by adipose tissue in
obesity, with the raised proportional conversion of glucose
to lactate, may be primarily a consequence of local hypoxia
within the tissue. Studies in mouse models have demonstrated
that hypoxia occurs in adipose tissue with obesity, oxygen
tension being up to 3-fold lower than in lean animals(16,17).
Limited hypoxia has also been reported in the tissue in obese
humans(18,19), although a recent report has cast doubts on
this(20). In cell culture studies, hypoxia has been shown to lead
to an increase in glucose uptake by adipocytes, this involving
recruitment of the GLUT1 facilitative GLUT(21,22). These changes
occur together with increased expression and secretion of a
number of inflammation-related adipokines, including vascu-
lar-endothelial-growth-factor, IL-6, leptin and Angptl4(23–26).
In parallel with the hypoxia-induced increase in glucose
uptake, lactate release from adipocytes is also augmented and
this again involves the recruitment of a specific transporter,
namely monocarboxylate transporter-1(27).
The hypoxia-induced elevation in lactate release by adipo-
cytes in obesity would be predicted to augment the inhibition
of lipolysis, by maximising the anti-lipolytic effect of insulin.
This could in turn increase the rate at which lipid accumulates
in adipocytes in obesity, perpetuating the expansion of adi-
pose tissue mass. However, a loss of insulin sensitivity is
characteristic of adipose tissue in the obese state, with hypoxia
itself leading to the rapid induction of insulin resistance(22,28).
Additional factors are, of course, also implicated in the
development of insulin resistance, including fatty acids and
specific adipokines, but its induction is likely to provide a
counter-regulatory brake on continuing net lipid deposition
in adipocytes.
In a recent clinical study, the ability of insulin to inhibit
lipolysis was found to be positively correlated with the oxygen
tension of adipose tissue(19). This is consistent with the concept
that adipose tissue hypoxia leads to an impairment in the sup-
pression of lipolysis by insulin and the dysregulation of the
local lactate autocrine/paracrine loop. An attenuation of the
local anti-lipolytic action of lactate in adipose tissue may
underlie raised NEFA release and circulating levels in obesity.
Lactate and fuel utilisation during exercise
The relative contribution of lipid and carbohydrate as energy
sources during exercise is dynamic. It is widely accepted
that at rest, lipid is the predominant fuel for muscle ATP syn-
thesis and that as exercise intensity increases, there is a shift in
fuel utilisation towards a greater reliance on carbohydrate.
This was described in the 1990s by Brooks & Mercier(29) as
the ‘cross-over concept’. Although the thesis was initially
much debated(30–32), the evidence for a reduction in fat oxi-
dation as the intensity of exercise increases is generally
accepted. However, identification and acceptance of an inte-
gral metabolic ‘switch’ responsible for the shift from lipid to
carbohydrate as the principal fuel during exercise has been
the subject of extensive discussion over many years.
Historically, early studies by Randle et al.(33) described what
is commonly referred to as the ‘glucose–fatty acid’ cycle. Their
early experiments in isolated rat cardiac and diaphragm
muscle identified specific reactions in glycolysis that are inhib-
ited by the presence of high fatty acid concentrations. Key
sites of inhibition include the pyruvate dehydrogenase com-
plex and phosphofructokinase, subsequent to elevated levels
of acetyl CoA and citrate, respectively. Studies in the
1990s(34–36) in which human participants performed exercise
at varying intensities of between 25 and 85 % of their
VO2max were not able to completely replicate the findings of
Randle. In these more recent studies, plasma NEFA levels
were artificially raised through intravenous infusion of lipid
and heparin emulsions, and while total fat oxidation was
increased and relative carbohydrate oxidation reduced, this
was largely due to slight reductions in glucose transport and
glycogenolysis in skeletal muscle.
Central to the debate on shifting fuel utilisation during exer-
cise has been the need to identify a locally derived factor of
either carbohydrate or lipid metabolism which may specifi-
cally inhibit the oxidation of the other. Another hypothesis
that has originated from studies in cardiac muscle(37) proposed
that a reduction in fat oxidation at high intensities was a result
of the inhibition by malonyl CoA of fatty acid transport into
the mitochondrial matrix mediated by carnitine palmitoyl
transferase-1. In brief, as glycolytic rates increase with increas-
ing carbohydrate catabolism, excess pyruvate production and
subsequent mitochondrial acetyl CoA production leads to an
accumulation of acetyl CoA in the muscle cytosol, where a
muscle-specific isoform of acetyl CoA carboxylase converts
this to malonyl CoA. Once again, however, confirmation of
this cycle in humans is not evident(38).
The exponential rise in muscle lactate production accompa-
nying muscle glycogen utilisation and coinciding with a
decrease in fatty acid oxidation, has been largely ignored by
those investigating the mechanisms of shifting fuel utilisation.
Particularly, if it is accepted that excess fatty acid availability
can result in an accumulation of acetyl CoA and subsequent
inhibition of pyruvate dehydrogenase, then some resultant
increase in lactate – the other metabolic pathway for pyruvate
– would be expected. The role of lactate accumulation in
muscle as exercise intensity increases has been largely con-
sidered in the debates centred on proton production and
muscle acidosis-based mechanisms of fatigue(39–44). Any
potential role of lactate as a regulator of fuel utilisation has
been discussed more as a potential endocrine factor regulating
adipose tissue lipolysis, and hence as a key feature in restrict-
ing NEFA availability for contracting muscles.
Rising plasma lactate and decreasing plasma NEFA
availability during exercise
The release of NEFA from subcutaneous adipose tissue during
exercise follows an inverted parabolic relationship. That is, as
intensity increases from rest, NEFA release into the systemic
blood supply increases until intensities of approximately
50–60 % of VO2max, at which point the release rates plateau
and subsequently decline as intensity continues to increase.
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B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
This has been described across a number of studies and
is classically represented in figures by Brooks(31,32). The
reduction in NEFA availability has been suggested to drive
the observed decline in fat oxidation as exercise intensity
increases. However, the evidence suggests that this is only
part of the explanation, and that other intracellular muscular
events are also at play(36), such as the role of malonyl CoA
described previously. Two widely discussed mechanisms,
described to explain the change in NEFA release from adipose
tissue as exercise intensity increases, have centred on:
(i) changes in adipose tissue blood flow(45–47) in which
elevated flow has accompanied elevated NEFA release at
low–moderate intensity exercise, and (ii) alternatively,
increasing plasma lactate levels(48,49) in which elevated
plasma lactate is associated with reduced NEFA release.
In 1974, men performing low-intensity exercise were
infused with lactate such that the plasma level was elevated
almost 9-fold above that observed without infusion(48). For
the same given exercise intensity, plasma NEFA and glycerol
levels were significantly reduced in the presence of elevated
plasma lactate. A year later, this finding was closely replicated
in dogs running on treadmills(49). These reports established
the basis for the view that muscle-derived lactate may act in
an endocrine manner to inhibit adipose tissue lipolysis.
While a specific mechanism was not obvious, speculation
pointed towards reduced fatty acid turnover resulting from
increased re-esterification(49). It is important to note, however,
that this view is not without contradiction. A study by
Ferrannini et al.(9) referred to earlier is often cited as showing
lactate infusion to have no effect on lipolysis. However, its rel-
evance in the context is doubtful since plasma lactate levels
were less than 3 mM (compared to approximately 9 mM in
the study of Boyd(48)) and infusion of lactate occurred
during both a resting state and/or a euglycaemic–hyperinsuli-
naemic clamp (compared to 90 min of exercise at 40 % VO2max
in the Boyd study(48)).
More recently, with the discovery of the lactate-binding
receptor (GPR81) in adipocytes(3), a mechanism by which
muscle-derived lactate could regulate adipose tissue lipolysis
was potentially realised. This was investigated using mice run-
ning on treadmills, and although plasma lactate levels of
10 mM were obtained together with a suppression of plasma
NEFA(4), a comparison between wild-type and GPR81-
deficient knockout mice provided strong evidence against
GPR81 as the target for an anti-lipolytic affect of lactate
during exercise.
The difficulty in collecting evidence for a direct mechanism,
as opposed to associative data, by which elevated muscle-
derived plasma lactate inhibits adipocyte lipolysis is not
surprising. There are many competing tissues for circulating
lactate during exercise, including the liver which can use it
as a precursor for gluconeogenesis, as well as cardiac and
oxidative skeletal muscle which may convert the metabolite
back to pyruvate and use it as a fuel for oxidative phosphoryl-
ation. Furthermore, given that the increased cardiac output
in exercise is generally accepted to direct blood flow towards
the working muscle, a mode by which circulating lactate could
be delivered to the adipose tissue would also need to be
identified. Blood flow redistribution away from peripheral
organs and the large influx of lactate into hepatic gluconeo-
genesis, or to other oxidative tissues, as more likely predomi-
nant sites of lactate action during exercise, make it difficult to
accept an endocrine function of myocyte-derived lactate on
adipose tissue. This is not to say, however, that lactate does
not have the potential to act locally, in an autocrine manner
to regulate fuel utilisation.
An autocrine lactate loop in myocytes regulating fuel
utilisation?
It is important to note that the outcome measure used to ident-
ify an anti-lipolytic affect of lactate during exercise has been
NEFA and/or glycerol in the circulation. However, an alterna-
tive view on the role of lactate in regulating fat metabolism
during exercise may be surmised from the outcome of studies
that measure fat oxidation per se through indirect calorimetry.
In this case, the focus is not on lactate regulating plasma NEFA
availability, but rather on lactate influencing what muscle can
actually do with the NEFA. For example, a distinct correlation
between rising plasma lactate levels and lowering rates of fat
oxidation is evident(50); in this particular study, participants
performed cycling exercise at a range of intensities between
low (approximately 40 % VO2max) and maximal intensity,
with plasma lactate concentration and whole body fat oxi-
dation assessed by ventilatory gases at each work intensity.
A major outcome was the relationship between the intensity
at which the first rise in plasma lactate concentration is
observed and the intensity at which maximal fat oxidation
occurs, such that further increases in plasma lactate were
associated with a subsequent decline in fat oxidation.
Until recently, a mechanism by which lactate could drive a
reduction in fat oxidation in muscle was not evident. It can, of
course, be argued that the reduced fat oxidation observed by
Achten & Jeukendrup(50) is secondary to the reduced fatty acid
availability that occurs as intensity increases, or as the authors
suggest, a result of acidosis-induced inhibition of carnitine
palmitoyl transferase-1-mediated fatty acid transport into mito-
chondria. However, with identification of GPR81 as a lactate
binding receptor on the plasma membrane of muscle, one
can argue that lactate could act locally in the tissue. Activation
by lactate of a muscle-specific GPR81 could result in local
inhibition of the lipolysis of intramyocellular lipids which
would thus further restrict NEFA availability at high intensities
and hence drive a subsequent reduction in fat oxidation
(see Fig. 1).
For this hypothesis to be applicable, in the first instance
confirmation of the presence of the functional GPR81 receptor
in muscle is required. While some recent reports have referred
to GPR81 expression being ‘exclusively’ or ‘solely restricted’ to
adipocytes(4,5), the original identification of lactate activation
of GPR81 observed GPR81 gene transcripts in human, rat
and mouse skeletal muscle, as well as protein expression in
mouse muscle(3). It should be noted that the mRNA levels
were substantially lower than those of adipose tissue and
that the protein expression assays were not performed in
either human or rat tissues. In addition, the protein detection
GPR81 receptor and the regulatory role of lactate 1313
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that was performed in mouse samples was in ‘crude plasma
membrane homogenates’, and as such potential contami-
nation from adipocytes in the homogenate cannot be ruled
out. Indeed, lactate derived from muscle during exercise
could have a powerful local action on those adipocytes associ-
ated with the musculo-skeletal system. Nevertheless, there is
a priori evidence for investigations on GPR81 expression in
muscle and its functions. It is tempting to speculate that lactate
produced during exercise has a specific role in regulating
muscle-specific fuel utilisation.
As described in an earlier section, isolated adipocyte studies
have shown GPR81 activation to be intrinsically linked to the
insulin-mediated inhibition of lipolysis and that this occurs
through G-protein coupled (Gi) inhibition of adenyl cyclase.
During exercise, insulin is not a major factor in regulating
fuel utilisation as its release from the pancreas is inhibited.
However, adenyl cyclase is central to the intracellular
response to adrenaline and glucagon activation of their
respective G-protein coupled receptors. Hence, GPR81
inhibition of adenyl cyclase could interfere with hormonal
activation of pathways regulating fuel oxidation during exer-
cise through suppressed cAMP-dependent protein kinase A
(PKA) activation. PKA is essential for the activation of the
muscle isoform of hormone-sensitive lipase, as well as of
other key regulatory enzymes in glycogen metabolism.
If substantiated, identification of a lactate-activated GPR81
signalling pathway in muscle would provide two major out-
comes for research in the nutritional biochemistry of exercise.
In the first instance, it could provide evidence for another
carbohydrate-derived factor directly limiting fat oxidation
(through HSL inhibition, as seen in adipocytes). This would
therefore reduce lipolysis of intramuscular lipid stores and
restrict NEFA availability within muscle independent of
plasma NEFA levels as exercise intensity increases. Secondly,
if the signalling pathway is as identified in the adipocyte
(Gi-induced suppressed cAMP), then the inhibited PKA
activity could have more global ramifications for fuel utilis-
ation and adaptation given the role of cAMP and PKA in
other enzyme systems, including cAMP response element
binding protein-mediated gene expression as well as
glycogen phosphorylase and glycogen synthase regulation of
glycogenolysis. Potentially, lactate may play a role as a nega-
tive-feedback loop limiting complete exhaustion of glycogen
at high intensities and peripheral catastrophe theorised fatigue
mechanisms.
ER
Adrenaline
↑ cAMP
↑ PKA
+–
+
↑ GlycogenolysisGlucose-6-phosphate
↑ Lactate
↑ Pyruvate
↑ Lipolysis↑ NEFAMitochondrial
OxPhos
MCT
↑ Lactate ↑ Lactate
Heart and/or oxidative muscle
liver
fat
GPR81
++
Fig. 1. Regulation of fuel utilisation in skeletal muscle during exercise. Adrenaline release and subsequent activation of a G-protein coupled receptor (ER) results
in elevated cyclic AMP (cAMP) levels and activation of protein kinase A (PKA). Two key targets of PKA include glycogen phosphorylase and hormone-sensitive
lipase, which result in elevated rates of glycogenolysis and lipolysis, respectively. Liberated NEFA can be oxidised within the mitochondria and contribute to ATP
re-synthesis through oxidative phosphorylation (OxPhos). Liberated glucose-6-phosphate drives elevated rates of glycolysis, leading to elevated pyruvate
production. Pyruvate can feed into mitochondrial OxPhos. As OxPhos approaches maximal rates, excess pyruvate production drives elevated rates of lactate
production within muscle cells. Lactate is transported from myocytes through a specific monocarboxylate transporter (MCT) and accumulates in the plasma.
Currently accepted theories suggest that the lactate can be taken up by the heart or other oxidative muscle for conversion to pyruvate and use in OxPhos; lactate
can be utilised by the liver as a source for gluconeogenesis or may be transported to adipose tissue where it acts to inhibit adipocyte lipolysis (all shown in filled
lines). The dashed lines represent the proposal that if skeletal muscle is shown to contain membrane bound GPR81, then it may facilitate an autocrine function of
lactate whereby a negative-feedback loop is identified. In this instance, rising cellular lactate concentrations act as a signal by which fat utilisation is restricted
(through reduced intramyocellular lipolysis) and carbohydrate oxidation becomes limiting (through reduced glycogenolysis). In the first instance, lactate serves as
a metabolic switch between fat and carbohydrate oxidation as exercise intensity increases and then as a peripheral signal of fatigue through limiting complete
exhaustion of glycogen stores.
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Conclusions
The identification of a selective G-coupled lactate receptor,
GPR81, which is principally expressed in adipose tissue has
provided a mechanistic basis for a metabolic signalling role
for lactate. Lactate inhibits lipolysis in adipocytes, and is the
route through which the anti-lipolytic action of insulin is
mediated. It is likely that the switch from lipid to carbohydrate
as a fuel by muscle during exercise is not directly due to the
lactate-induced inhibition of lipolysis in adipose tissue.
However, it is conceivable that there is an autocrine loop in
muscle in which lactate inhibits intramuscular lipid mobilis-
ation through a GPR81 receptor in myocytes. The increased
production of lactate by adipocytes in obesity as a conse-
quence of adipose tissue hypoxia is unlikely to have a
major effect on the anti-lipolytic action of insulin, since insulin
resistance is a characteristic of the tissue in the obese. It is
increasingly evident, nonetheless, that lactate is an important
metabolic signal.
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